The transition from testing the dead to testing the living is the latest example of how genomics is expanding horizons for ...

The firm saw a 26 percent increase in screening revenue and a 14 percent increase in precision oncology revenue during the quarter.

The company plans to begin using the instrument in its Burlington, North Carolina, lab in the first quarter of the year and then move the technology into other facilities.

Artificial intelligence firm Athelas announced on Thursday that its Athelas Home hematology analyzer has received clearance from the US Food and Drug Administration for use in point-of-care settings.

The firm expects to acquire Lex Diagnostics when its Velo rapid PCR system is cleared by the FDA. The review has been ongoing since June.

NEW YORK – The US Food and Drug Administration on Tuesday issued a warning letter to ProDx Health, alleging the firm was offering human immunodeficiency virus sample self-collection kits without ...

Under the agreement, Labcorp will become the clinically integrated laboratory provider of choice for all SOMOS providers, care teams, and patients.

Last week, readers were most interested in a story about the growing use of blood-based tests for patients who may have Alzheimer's but show no symptoms.

The firm's consumer-initiated testing business grew year over year by more than 20 percent in 2025, generating roughly $250 million in revenue.

While still in an early stage, interest in testing asymptomatic patients is growing as drug developers explore treating ...

NEW YORK – Following the completion of Waters' acquisition of Becton Dickinson's biosciences and diagnostics business, investment bank Barclays said on Tuesday that it has reinstated coverage of ...

In fiscal Q1 2026, total revenue for the Life Sciences unit declined to $766 million from $836 million in fiscal Q1 2025. Within Life Sciences, Diagnostic Solutions revenue declined 7 percent to $439 ...